PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24603476-13	2014	CONCLUSIONS: The mTOR pathway was activated in IgAN rats and the early application of low-dose mTOR inhibitor rapamycin may slow the renal injury of IgAN in rats.	Sirolimus	110-119	IGAN1	Homo sapiens	47-51	
24603476-13	2014	CONCLUSIONS: The mTOR pathway was activated in IgAN rats and the early application of low-dose mTOR inhibitor rapamycin may slow the renal injury of IgAN in rats.	Sirolimus	110-119	IGAN1	Homo sapiens	149-153	
28427080-0	2017	Rapamycin Induces Autophagy and Reduces the Apoptosis of Podocytes Under a Stimulated Condition of Immunoglobulin A Nephropathy.	Sirolimus	0-9	IGAN1	Homo sapiens	99-127	
28427080-1	2017	Backgroud/Aims: The aim of this study was to investigate the potential renoprotective effect of rapamycin on the autophagy of podocytes treated with the supernatant of mesangial cells cultured with aggregated IgA1 (aIgA1) from immunoglobulin A nephropathy (IgAN) patients.	Sirolimus	96-105	IGAN1	Homo sapiens	227-255	
28427080-1	2017	Backgroud/Aims: The aim of this study was to investigate the potential renoprotective effect of rapamycin on the autophagy of podocytes treated with the supernatant of mesangial cells cultured with aggregated IgA1 (aIgA1) from immunoglobulin A nephropathy (IgAN) patients.	Sirolimus	96-105	IGAN1	Homo sapiens	257-261	
26297427-10	2015	Our results showed that p70S6K, S6 and Akt phosphorylation were significantly upregulated in IgAN rats, and rapamycin effectively inhibited p70S6K and S6 phosphorylation.	Sirolimus	108-117	IGAN1	Homo sapiens	93-97	
26297427-13	2015	In conclusion, the Akt/mTOR/p70S6K pathway was activated in IgAN, and our findings suggested that rapamycin may represent a viable option for the treatment of IgAN.	Sirolimus	98-107	IGAN1	Homo sapiens	60-64	
26297427-13	2015	In conclusion, the Akt/mTOR/p70S6K pathway was activated in IgAN, and our findings suggested that rapamycin may represent a viable option for the treatment of IgAN.	Sirolimus	98-107	IGAN1	Homo sapiens	159-163	
24869763-6	2014	Recurrent IgAN was diagnosed in 27 of 124 (22%) patients in clinically indicated kidney allograft biopsies over a median follow-up of 6.86 +- 5.4 yr. On cox proportional hazards model multivariate analysis, the hazard risk (HR) of IgAN recurrence was significantly higher in patients managed with steroid-free (HR 8.59: 3.03, 24.38, p < 0.001) and sirolimus-based (HR = 3.00:1.16, 7.75, p = 0.024) immunosuppression without antilymphocyte globulin induction (HR = 4.5: 1.77, 11.73, p = 0.002).	Sirolimus	351-360	IGAN1	Homo sapiens	10-14